UK Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Jan. 1, 2007 - 75 Pages

Table of Contents

Chapter 1 - Executive Summary

UK Pharmaceuticals & Healthcare Industry SWOT

United Kingdom Political SWOT

United Kingdom Economic SWOT

Chapter 2 - Business Environment Rankings

Western Europe Region

Table: Western Europe Business Environment Rankings

Business Environment Ranking

Economics - Long Term risk

Politics - Long Term risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - UK: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Issues

Pricing and Reimbursement Issues

Chapter 5 - Industry Developments

Healthcare sector

Pharmaceuticals Industry

Foreign Sector

R&D Sector

OTC Sector

Retail Sector

Parallel Imports

Table: Savings From Parallel Imports In 2004 (EURmn)

Regional Developments

Health Tourism

Manufacturing Sector

Wholesale sector

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: United Kingdom Drug Market Forecast Indicators

Key Growth Factors - Industry

Table: United Kingdom Research & Development (R&D) Forecast Indicators

Key Growth Factors - Macroeconomic

Table: United Kingdom - Macroeconomic Forecasts

Prescription Market Forecast

Table: United Kingdom Prescription Drugs Market Forecast Indicators

OTC Market Forecast

Table: United Kingdom OTC Market Forecast Indicators

Generics and Branded Market Forecasts

Table: United Kingdom Generics And Branded Market Forecast Indicators

Export/Import Forecasts

Table: United Kingdom Sectoral Trade Forecast Indicators

Chapter 7 - Company Profiles

Leading Multinational Manufacturers

Pfizer

Novartis

Sanofi-Aventis

Merck & Co

Leading Indigenous Manufacturers

GSK

AstraZeneca

Chapter 8 - BMI Forecast Modelling

How we generate our industry forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 9 - Country Snapshot: UK Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Abstract

The UK pharmaceuticals industry is characterised by an unpopular cost-effectiveness regulator, pioneering OTC switches, a robust clinical trials sector and by being a favoured destination for parallel traded medicines, according to BMI's recently published ""United Kingdom Pharmaceuticals & Healthcare Report Q3 2006"". Despite government cost-containment measures, the size of the market is expected to grow in the mid-tem, albeit at rates below those seen over the last decade. Currently, the market is valued at US$25bn and it is expected to reach over US$32bn by 2010.

NICE - the country's cost-effectiveness regulator - is causing much distress to patients by preventing the newest drugs from being available on the National Health Service (NHS), leaving sick individuals to pay for the often lifesaving products themselves. In August 2006, NICE deemed that two breakthrough colon cancer drugs were too expensive despite being safe, highly effective, easier to tolerate than traditional chemotherapy, and available in every other EU country. Meanwhile, Japanese firm Eisai has petitioned the UK government to investigate why NICE is restricting patient access to its breakthrough Alzheimer's disease drug Aricept (donepezil).

BMI's adjusted Business Environment Rankings for Western Europe reveal that the UK has moved down a place to third, behind Switzerland and Germany. The primary reason for the drop is the country's worsening regulatory environment. Because of the dominance of the domestic multinationals - GlaxoSmithKline (GSK) and AstraZeneca - the UK also scores poorly for domestic sector threat. However, the country's political and economic risk is among the most favourable worldwide, which underpins its lofty position in the rankings.

The NHS is not seeing value for money from the extra billions of pounds that it has been given, with bureaucracy primarily to blame, according a recent report. Since 2002, the budget of the NHS has increased by approximately 7% per annum and is projected to reach GBP92.6bn (US$176bn) by the 2007-8 fiscal year. Among the thousands of new staff working in the NHS, the single biggest increase has been in the number of managers, up by 58%.

Empowering patients and reducing the burden on healthcare providers, the UK reclassified several medicines from either prescription-only medicine to pharmacy-only, or pharmacy-only to general sales list in September 2006, partly to reflect recent changes in national, European or international recommendations. GSK's Imigran (sumatriptan) for the acute relief of migraine is among the products now available over-the-counter.

Key Benefits of Report

Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.

Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments

Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.